Male Lower Urinary Tract Symptoms – Epidemiology – Epidemiology Dashboard
DRG Epidemiology's coverage of male LUTS comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of male LUTS for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology's male LUTS forecast will answer the following questions:
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of male LUTS over the forecast period?
Of all people with male LUTS, how many in each country across the major mature pharmaceutical markets have been formally diagnosed?
Of all people diagnosed with male LUTS, how many in each country across the major mature pharmaceutical markets are drug-treated?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following male LUTS subpopulations:
Total prevalent cases by severity status
Total prevalent cases by diagnosis status
Total prevalent cases by comorbid ED
Diagnosed prevalent cases by drug-treatment status
Male Lower Urinary Tract Symptoms - Epidemiology - Epidemiology Dashboard
Introduction
MLUTS Epidemiology Dashboard
Stephanie Niquita
Stephanie Niquita Phankon, M.B.B.S., M.P.H.,is a senior epidemiologist at DRG, part of Clarivate. She trained as a community physician and has supervised and coordinated various governmental and nongovernmental public health projects. She holds an M.P.H. specializing in epidemiology from the Tata Institute of Social Sciences in Mumbai and a medical degree from Hubei University of Chinese Medicine in the People’s Republic of China.
Abey John, M.P.H.
Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.
